The latest biotech news - Labiotech.eu

Home News and Trends Page 230

Latest Posts

EMA decision amsterdam 1

News and Trends 21 Nov 2017

Welcome to Amsterdam, EMA! Your New Home Post-Brexit

Last year’s Brexit vote left the European Medicines Agency (EMA) searching for a new home. Last night, it was revealed that it will relocate to Amsterdam. Yesterday, representatives from each of the member states voted for the new location of the European Medicines Agency (EMA). In the end, it came down to a coin toss that […]

November 21, 2017 - 3 minutesmins - By Alex Dale

Trim Away protein function2 1

News and Trends 20 Nov 2017

British and German Scientists Chuck Proteins in the Trash to Uncover their Function

Trim-Away removes a protein to uncover its true function, which will support disease research and potentially the development of new therapies. Scientists at the Medical Research Council in the UK and the Max Planck Institute in Germany have discovered Trim-Away, a new technique that can remove a protein from a cell so that its true function can […]

November 20, 2017 - 3 minutesmins - By Alex Dale

DBV Technologies Peanut Allergy

News and Trends 20 Nov 2017

After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy

DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […]

November 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Genmab darzalex 1B blockbuster 1

News and Trends 17 Nov 2017

Welcome to the Blockbuster Club, Genmab!

Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of the biotech world by achieving $1B (€850M) in sales of its drug for multiple myeloma, Darzalex. The biotech will now receive milestone payments of $50M (€42M) […]

November 17, 2017 - 3 minutesmins - By Alex Dale

antibiotic resistance motif bio2 1

News and Trends 17 Nov 2017

British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance

Update (17/11/2017): Motif Bio will raise up to $20M (€17M) in the form of a loan from US firm Hercules Capital. The funds will be used to fund the pre-commercialization stage of iclaprim, a new antibiotic that is expected to be launched in the US in 2019. Originally published on 04/10/2017 Iclaprim is a new antibiotic […]

November 17, 2017 - 3 minutesmins - By Alex Dale

cancer sensor tp53 germany 1

News and Trends 16 Nov 2017

German Cancer Sensor Raises the Alarm and Puts the Fire Out

No need to call the fire brigade! The University of Dresden’s cancer sensor spots a mutation to p53, the most important cancer gene, and kills the cell. Researchers at the University of Dresden, Germany, have developed a molecular sensor that detects a mutation in tumor protein p53 – implicated in 50% of cancers – and kills […]

November 16, 2017 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

hummingbird diagnostics cancer alzheimer parkinson

News and Trends 16 Nov 2017

German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s

Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […]

November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

prostate cancer parasite norway2 1

News and Trends 16 Nov 2017

Anti-Parasite Drug May Help to Treat Prostate Cancer, Say Norwegian Scientists

Researchers in Norway have found that a drug used to kill parasites like tapeworms can slow the growth of prostate and colon cancer cells. A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and […]

November 16, 2017 - 3 minutesmins - By Alex Dale

HIV vaccination primates Germany 1

News and Trends 16 Nov 2017

German Scientists Test Out New HIV Vaccine Combinations in Animals

Scientists from the German Primate Center have investigated the impact of the delivery route and order of components on the success of an HIV vaccine. With more than 36 million people infected with the human immunodeficiency virus (HIV) and a further 2.4 million infected each year, something needs to be done. Researchers from the German […]

November 16, 2017 - 3 minutesmins - By Alex Dale

neophore cancer small molecules £3M

News and Trends 15 Nov 2017

New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer

NeoPhore, has received investment from Sixth Element Capital to develop small molecules that stimulate the immune system against cancer. Sixth Element Capital has invested £3M (€3.3M) in NeoPhore, a new spin-out from PhoreMost – a drug discovery company based in Cambridge, UK. NeoPhore has been set up to explore small molecules that could be used to stimulate […]

November 15, 2017 - 1 minutemin - By Alex Dale

moderna biontech personalized cancer vaccine

News and Trends 15 Nov 2017

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Xeltis heart valves series c2 1

News and Trends 15 Nov 2017

Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves

Xeltis has raised a €45M Series C to boost the development of its pioneering medical device, RestoreX, which helps to replace damaged heart valves. Xeltis, based in Zurich, Switzerland, is a clinical-stage medical device company developing heart valves and blood vessels to allow the body to naturally restore heart valve function. The biotech has achieved a €45M […]

November 15, 2017 - 2 minutesmins - By Alex Dale

ADVERTISEMENT